Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles
The most common approach to in vivo pharmacokinetic and pharmacodynamic modeling involves sequential analysis of the plasma concentration versus time and then response versus time data, such that the plasma kinetic model provides an independent function, driving the dynamics. However, response versus time data, even in the absence of measured drug concentrations, inherently contain useful information about the turnover characteristics of response (turnover rate, half‐life of response), the drug's biophase kinetics (F, half‐life) as well as the pharmacodynamic characteristics (potency, intrinsic activity). Previous analyses have assumed linear kinetics, linear dynamics, no time lag between kinetics and dynamics (single‐valued response), and time constant parameters. However, this report demonstrates that the drug effect can be indirect (antinociception, cortisol/adrenocorticotropin (ACTH), body temperature), display nonlinear kinetics, display back mechanisms (nonstationarity, cortisol/ACTH) and exhibit hysteresis with the drug levels in the biophase (antinociception, body temperature). It is also demonstrated that crucial determinants of the success of modeling dose–response–time data are the dose selection, multiple dosing, and to some extent different input rates and routes. This report exemplifies the possibility of assigning kinetic forcing functions in pharmacodynamic modeling in both preclinical and clinical studies for the purpose of characterizing (discrimination between turnover and drug‐specific parameters) response data and optimizing subsequent clinical protocols, and for identification of inter‐individual differences. Copyright © 2000 John Wiley & Sons, Ltd.
Number of times cited: 33
- Mario González‐Sales, Fahima Nekka, Mario Tanguay, Pierre‐Olivier Tremblay and Jun Li, Modelling the dose–response relationship: the fair share of pharmacokinetic and pharmacodynamic information, British Journal of Clinical Pharmacology, 83, 6, (1240-1251), (2017).
- Robert Andeon, Mats Jirstrand, Lambertus Peletier, Michael J. Chappell, Neil D. Evans and Johan Gabrielsson, Dose–response-time modelling: Second-generation turnover model with integral back control, European Journal of Pharmaceutical Sciences, 81, (189), (2016).
- Panos Macheras and Athanassios Iliadis, Nonclassical Pharmacodynamics, Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics, 10.1007/978-3-319-27598-7_13, (361-403), (2016).
- F. T. Musuamba, D. Teutonico, H. J. Maas, A. Facius, S. Yang, M. Danhof and O. Della Pasqua, Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD), Pharmaceutical Research, 32, 2, (617), (2015).
- Markus R. Lange and Heinz Schmidli, Analysis of clinical trials with biologics using dose–time‐response models, Statistics in Medicine, 34, 22, (3017-3028), (2015).
- Fredrik Iredahl, Veeranjaneyulu Sadda, Liam J. Ward, Johannes Hackethal, Simon Farnebo, Erik Tesselaar and Folke Sjöberg, Modeling Perfusion Dynamics in the Skin During Iontophoresis of Vasoactive Drugs Using Single‐Pulse and Multiple‐Pulse Protocols, Microcirculation, 22, 6, (446-453), (2015).
- Wojciech Krzyzanski, Juan Jose Perez-Ruixo and John Harrold, Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice, Journal of Pharmacokinetics and Pharmacodynamics, 42, 6, (709), (2015).
- Erno van Schaick, Jenny Zheng, Juan Jose Perez Ruixo, Ronald Gieschke and Philippe Jacqmin, A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-015-9423-3, 42, 4, (315-332), (2015).
- Lambertus A. Peletier and Johan Gabrielsson, Challenges in Pharmacology Modelling, Journal of Dynamics and Differential Equations, 27, 3-4, (941), (2015).
- Markus R. Lange and Heinz Schmidli, Optimal design of clinical trials with biologics using dose‐time‐response models, Statistics in Medicine, 33, 30, (5249-5264), (2014).
- Johan Gabrielsson and Lambertus A. Peletier, Dose–response–time data analysis involving nonlinear dynamics, back and delay, European Journal of Pharmaceutical Sciences, 59, (36), (2014).
- Juan Jose Perez Ruixo, Sameer Doshi, Yow‐Ming C. Wang and Diane R. Mould, Romiplostim dose–response in patients with myelodysplastic syndromes, British Journal of Clinical Pharmacology, 75, 6, (1445-1454), (2013).
- E. BERMINGHAM, J. R. E. Del CASTILLO, C. LAINESSE, K. PASLOSKE and S. RADECKI, Demonstrating bioequivalence using clinical endpoint studies, Journal of Veterinary Pharmacology and Therapeutics, 35, s1, (31-37), (2012).
- William J. Jusko, Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values, Pharmaceutical Research, 29, 9, (2628), (2012).
- Petra M. Jauslin, Mats O. Karlsson and Nicolas Frey, Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose‐Insulin Model, The Journal of Clinical Pharmacology, 52, 12, (1861-1871), (2013).
- J. J. Perez-Ruixo, B. Green, S. Doshi, Y.-M. Wang and D. R. Mould, Romiplostim Dose Response in Patients With Immune Thrombocytopenia, The Journal of Clinical Pharmacology, 52, 10, (1540), (2012).
- Kai Wu, Michael Looby, Goonaseelan Pillai, Gregory Pinault, Anton Franz Drollman and Steve Pascoe, Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients, Journal of Pharmacokinetics and Pharmacodynamics, 38, 1, (105), (2011).
- A‐K Hamberg, M Wadelius, J D Lindh, M L Dahl, R Padrini, P Deloukas, A Rane and E N Jonsson, A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age, Clinical Pharmacology & Therapeutics, 87, 6, (727-734), (2010).
- Richard L. Lalonde, PHARMACODYNAMICS, Pharmacology and Therapeutics, 10.1016/B978-1-4160-3291-5.50018-4, (203-218), (2009).
- Amelia Ramon-Lopez, Ricardo Nalda-Molina, Belen Valenzuela and Juan Jose Perez-Ruixo, Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients, Pharmaceutical Research, 26, 8, (1952), (2009).
- Hala Abou hammoud, Nicolas Simon, Saik Urien, Bruno Riou, Philippe Lechat and Frédéric Aubrun, Intravenous morphine titration in immediate postoperative pain management: Population kinetic–pharmacodynamic and logistic regression analysis, Pain, 144, 1, (139), (2009).
- Johan Gabrielsson, Hugues Dolgos, Per-Göran Gillberg, Ulf Bredberg, Bert Benthem and Göran Duker, Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations, Drug Discovery Today, 14, 7-8, (358), (2009).
- Yvonne Y. Lau, Peiming Ma, Leonid Gibiansky, Renee Komorowski, Jin Wang, George Wang, Hai Yan, Murielle M. Véniant and Tarundeep Kakkar, Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice, The AAPS Journal, 10.1208/s12248-009-9150-z, 11, 4, (700-709), (2009).
- M. Tod, Evaluation of drugs in pediatrics using K‐PD models: perspectives, Fundamental & Clinical Pharmacology, 22, 6, (589-594), (2008).
- Richard N Upton, Mads Rasmussen, Cliff Grant, Allison M Martinez, Georg E Cold and Guy L Ludbrook, PHARMACOKINETICS AND PHARMACODYNAMICS OF INDOMETHACIN: EFFECTS ON CEREBRAL BLOOD FLOW IN ANAESTHETIZED SHEEP, Clinical and Experimental Pharmacology and Physiology, 35, 3, (317-323), (2007).
- T J Steeg, J Freijer, M Danhof and E C M Lange, Pharmacokinetic‐pharmacodynamic modelling of S(−)‐atenolol in rats: reduction of isoprenaline‐induced tachycardia as a continuous pharmacodynamic endpoint, British Journal of Pharmacology, 151, 3, (356-366), (2009).
- Jasper Dingemanse and Silke Appel-Dingemanse, Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development, Clinical Pharmacokinetics, 10.2165/00003088-200746090-00001, 46, 9, (713-737), (2007).
- Anna Lönnebo, Anders Grahnén and Mats O. Karlsson, An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers, British Journal of Clinical Pharmacology, 64, 2, (125-132), (2007).
- Christoffer Bundgaard, Frank Larsen, Martin Jørgensen and Arne Mørk, Pharmacokinetic/Pharmacodynamic Feedback Modelling of the Functional Corticosterone Response in Rats after Acute Treatment with Escitalopram, Basic & Clinical Pharmacology & Toxicology, 100, 3, (182-189), (2007).
- P. Jacqmin, E. Snoeck, E.A. van Schaick, R. Gieschke, P. Pillai, J.-L. Steimer and P. Girard, Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-006-9035-z, 34, 1, (57-85), (2006).
- Serge C L M Cremers, Goonaseelan (Colin) Pillai and Socrates E Papapoulos, Pharmacokinetics/Pharmacodynamics of Bisphosphonates, Clinical Pharmacokinetics, 44, 6, (551), (2005).
- Jan Lötvall, Mona Palmqvist, Jaro Ankerst, Gunnar Peon, Johan Rosenborg, Thomas Bengtsson, Zsuzsanna Rott, Magdolna Poczi, Ágnes Devai and Bertil Waldeck, The effect of formoterol over 24h in patients with asthma: the role of enantiomers, Pulmonary Pharmacology & Therapeutics, 18, 2, (109), (2005).
- Rasmus Jansson-Löfmark and Peter Gennemark, Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs, Nucleic Acid Therapeutics, 10.1089/nat.2018.0739, (2018).